kwkw
2021-10-27
Like pls
GlaxoSmithKline reports Q3 results, boost FY21 outlook
免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP,发表看法
APP内打开
发表看法
3
3
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":855336523,"tweetId":"855336523","gmtCreate":1635334518490,"gmtModify":1635334518490,"author":{"id":4096539860875570,"authorId":4096539860875570,"authorIdStr":"4096539860875570","name":"kwkw","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":3,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Like pls</p></body></html>","htmlText":"<html><head></head><body><p>Like pls</p></body></html>","text":"Like pls","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/855336523","repostId":1192607469,"repostType":4,"repost":{"id":"1192607469","pubTimestamp":1635334185,"share":"https://www.laohu8.com/m/news/1192607469?lang=&edition=full","pubTime":"2021-10-27 19:29","market":"us","language":"en","title":"GlaxoSmithKline reports Q3 results, boost FY21 outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=1192607469","media":"seekingalpha","summary":"GlaxoSmithKline(NYSE:GSK): Q3 Non-GAAP EPS of £0.37; GAAP EPS of £0.23.\nRevenue of £9.1B (+5% Y/Y)\nS","content":"<ul>\n <li>GlaxoSmithKline(NYSE:GSK): Q3 Non-GAAP EPS of £0.37; GAAP EPS of £0.23.</li>\n <li>Revenue of £9.1B (+5% Y/Y)</li>\n <li>Sales growth across Pharmaceuticals, Vaccines and Consumer Healthcare driven by strong commercial execution and underlying demand</li>\n <li>Pharmaceuticals £4.4 billion +5% AER, +10% CER with growth in New and Specialty medicines +24% CER; Respiratory +33% CER; Immuno-inflammation +32% CER ex-COVID-19 solutions; Oncology +34% CER; total HIV +8% CER • Vaccines £2.2 billion +7% AER, +13% CER with Shingrix £502 million +41% CER</li>\n <li>COVID-19 solutions sales £209 million; Xevudy £114 million and pandemic adjuvant £94 million</li>\n <li>Consumer Healthcare £2.5 billion +3% AER, +8% CER (+10% excluding divestments/brands under review)</li>\n <li>2021 EPS guidance improved and reconfirm 2022 outlook • Now expect 2021 Adjusted EPS to decline between -2% to -4% at CER excluding COVID-19 solutions, previously mid-to-high single digit decline</li>\n <li>Now expect 2021 Adjusted EPS contribution from COVID-19 solutions of 7% to 9% at CER</li>\n <li>Expectation for meaningful improvement in revenues and margins in 2022 reconfirmed</li>\n <li>2022 outlook excludes any contribution from COVID-19 solutions.</li>\n <li>Dividend of 19p declared for Q3 2021. Continue to expect 80p/share for 2021</li>\n</ul>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GlaxoSmithKline reports Q3 results, boost FY21 outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlaxoSmithKline reports Q3 results, boost FY21 outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-27 19:29 GMT+8 <a href=https://seekingalpha.com/news/3758818-glaxosmithkline-reports-q3-results-boost-fy21-outlook><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>GlaxoSmithKline(NYSE:GSK): Q3 Non-GAAP EPS of £0.37; GAAP EPS of £0.23.\nRevenue of £9.1B (+5% Y/Y)\nSales growth across Pharmaceuticals, Vaccines and Consumer Healthcare driven by strong commercial ...</p>\n\n<a href=\"https://seekingalpha.com/news/3758818-glaxosmithkline-reports-q3-results-boost-fy21-outlook\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GSK":"葛兰素史克"},"source_url":"https://seekingalpha.com/news/3758818-glaxosmithkline-reports-q3-results-boost-fy21-outlook","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1192607469","content_text":"GlaxoSmithKline(NYSE:GSK): Q3 Non-GAAP EPS of £0.37; GAAP EPS of £0.23.\nRevenue of £9.1B (+5% Y/Y)\nSales growth across Pharmaceuticals, Vaccines and Consumer Healthcare driven by strong commercial execution and underlying demand\nPharmaceuticals £4.4 billion +5% AER, +10% CER with growth in New and Specialty medicines +24% CER; Respiratory +33% CER; Immuno-inflammation +32% CER ex-COVID-19 solutions; Oncology +34% CER; total HIV +8% CER • Vaccines £2.2 billion +7% AER, +13% CER with Shingrix £502 million +41% CER\nCOVID-19 solutions sales £209 million; Xevudy £114 million and pandemic adjuvant £94 million\nConsumer Healthcare £2.5 billion +3% AER, +8% CER (+10% excluding divestments/brands under review)\n2021 EPS guidance improved and reconfirm 2022 outlook • Now expect 2021 Adjusted EPS to decline between -2% to -4% at CER excluding COVID-19 solutions, previously mid-to-high single digit decline\nNow expect 2021 Adjusted EPS contribution from COVID-19 solutions of 7% to 9% at CER\nExpectation for meaningful improvement in revenues and margins in 2022 reconfirmed\n2022 outlook excludes any contribution from COVID-19 solutions.\nDividend of 19p declared for Q3 2021. Continue to expect 80p/share for 2021","news_type":1},"isVote":1,"tweetType":1,"viewCount":28,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":7,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/855336523"}
精彩评论